X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with SUVEN LIFE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs SUVEN LIFE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES SUVEN LIFE VENUS REMEDIES/
SUVEN LIFE
 
P/E (TTM) x -711.4 19.8 - View Chart
P/BV x 0.2 3.7 5.7% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 VENUS REMEDIES   SUVEN LIFE
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
SUVEN LIFE
Mar-16
VENUS REMEDIES/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs218339 64.4%   
Low Rs82144 56.9%   
Sales per share (Unadj.) Rs365.639.2 931.6%  
Earnings per share (Unadj.) Rs1.57.5 19.9%  
Cash flow per share (Unadj.) Rs37.98.8 432.1%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs382.549.0 780.7%  
Shares outstanding (eoy) m11.44127.28 9.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.46.2 6.7%   
Avg P/E ratio x101.032.4 312.0%  
P/CF ratio (eoy) x4.027.5 14.4%  
Price / Book Value ratio x0.44.9 8.0%  
Dividend payout %026.8 0.0%   
Avg Mkt Cap Rs m1,71730,732 5.6%   
No. of employees `0001.01.0 106.9%   
Total wages/salary Rs m324416 77.9%   
Avg. sales/employee Rs Th4,100.75,236.1 78.3%   
Avg. wages/employee Rs Th318.0436.5 72.9%   
Avg. net profit/employee Rs Th16.7995.5 1.7%   
INCOME DATA
Net Sales Rs m4,1834,995 83.7%  
Other income Rs m20194 10.4%   
Total revenues Rs m4,2035,189 81.0%   
Gross profit Rs m8121,233 65.8%  
Depreciation Rs m417167 249.3%   
Interest Rs m38054 700.7%   
Profit before tax Rs m351,205 2.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m18255 7.1%   
Profit after tax Rs m17950 1.8%  
Gross profit margin %19.424.7 78.6%  
Effective tax rate %51.621.2 243.6%   
Net profit margin %0.419.0 2.1%  
BALANCE SHEET DATA
Current assets Rs m2,7714,986 55.6%   
Current liabilities Rs m1,9311,042 185.3%   
Net working cap to sales %20.179.0 25.4%  
Current ratio x1.44.8 30.0%  
Inventory Days Days12561 205.0%  
Debtors Days Days5439 137.3%  
Net fixed assets Rs m5,3283,126 170.5%   
Share capital Rs m114127 89.9%   
"Free" reserves Rs m4,1773,717 112.4%   
Net worth Rs m4,3766,236 70.2%   
Long term debt Rs m1,911432 441.9%   
Total assets Rs m8,4288,079 104.3%  
Interest coverage x1.123.2 4.7%   
Debt to equity ratio x0.40.1 629.8%  
Sales to assets ratio x0.50.6 80.3%   
Return on assets %4.712.4 37.9%  
Return on equity %0.415.2 2.6%  
Return on capital %6.618.9 35.0%  
Exports to sales %087.5 0.0%   
Imports to sales %20.512.2 167.8%   
Exports (fob) Rs mNA4,371 0.0%   
Imports (cif) Rs m858611 140.5%   
Fx inflow Rs m04,666 0.0%   
Fx outflow Rs m858942 91.1%   
Net fx Rs m-8583,724 -23.0%   
CASH FLOW
From Operations Rs m469922 50.8%  
From Investments Rs m29-619 -4.7%  
From Financial Activity Rs m-464-698 66.4%  
Net Cashflow Rs m35-396 -8.7%  

Share Holding

Indian Promoters % 32.9 63.4 51.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.0 -  
FIIs % 0.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 36.5 181.9%  
Shareholders   20,121 37,287 54.0%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  STRIDES SHASUN LTD  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Feb 16, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS